glp 1 va study Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort VAResearchNewsBrief: Orlando VA Healthcare System

This typically follows confirmed diagnosis of B12 deficiency through blood tests and clinical assessment

The group at highest risk of increase for severe endocrine ophthalmopathy involves those with eye manifestation who continue to smoke

The renoprotective potential of pentoxifylline in chronic kidney disease

WO2003045373A1 - Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie's disease - Google Patents Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie's disease Download PDF Info Publication number WO2003045373A1 WO2003045373A1 PCT/IT2002/000745 IT0200745W WO03045373A1 WO 2003045373 A1 WO2003045373 A1 WO 2003045373A1 IT 0200745 W IT0200745 W IT 0200745W WO 03045373 A1 WO03045373 A1 WO 03045373A1 Authority WO WIPO (PCT) Prior art keywords disease carnitine peyronie propionyl medicine Prior art date Legal status (The legal status is an assumption and is not a legal conclusion